Structural basis for the inhibition of Trypanosoma brucei enolase by a camelid single-domain antibody
Zeng LiiD, Natalia SmiejkowskaiD, Julie Vansevenant, Jimmy Mertens, Pieter Van WielendaeleiD, Joar Esteban Pinto Torres, Stefan MageziD, Yann G.‐J. SterckxiD
Abstract
Trypanosoma brucei is an extracellular protozoan that causes neglected tropical diseases in both humans and livestock. The parasite has a bipartite life cycle involving an insect vector and a mammalian host. Within the latter, it mainly thrives as a blood-borne parasite that relies on glycolysis to support its energy metabolism. It is for this reason that trypanosomal glycolytic enzymes have been investigated as potential targets for the development of trypanosome-killing drugs. Recent work from our lab has shown that they are also interesting biomarkers for the detection of active trypanosome infections. T. brucei enolase (TbrENO) is a trypanosomal glycolytic enzyme that has gathered interest in both drug and diagnostics development. In this paper, we report the discovery of a camelid single domain antibody (sdAb aka nanobody) that specifically recognises and inhibits TbrENO. The sdAbs inhibitory mechanism is unraveled through a combination of protein biochemistry, biophysics, and structural biology. Author summaryTrypanosoma brucei is a unicellular parasite that lives in the bloodstream of humans and animals, where it causes serious but often overlooked diseases. Because it depends heavily on breaking down glucose to produce energy, the parasites glucose-processing proteins (called glycolytic enzymes) have become important targets for both new treatments and improved diagnostic tools. One of these proteins, called T. brucei enolase (TbrENO), has recently drawn attention for its potential in drug development and disease detection. In this study, we discovered a special type of antibody, known as a camelid single-domain antibody (sdAb aka nanobody), that can specifically recognize and block the activity of TbrENO. We employed a combination of various laboratory techniques to understand exactly how the sdAb binds to and inhibits the enzyme. Our findings provide new insight into how TbrENO can be inhibited in a way that does not require active site binding and highlight the value of sdAbs as precise tools for targeting key parasite proteins.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 4.61
- Field percentile
- top 11%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Allosteric inhibition of trypanosomatid pyruvate kinases by a camelid single-domain antibody
Joar Esteban Pinto Torres, Mathieu Claes, … Yann G.‐J. Sterckx·eLifePeer-reviewed·Aug 21, 2024
- In silico identification of putative Trypanosoma cruzi enolase inhibitors
E. Valera-Vera, M. Saye, … C. A. Pereira·bioRxiv·Jun 27, 2019
- An African trypanosome surface protein inhibits amplification of the complement system
Alexander D. Cook, Helena Webb, … Matthew K. Higgins·bioRxiv·Aug 20, 2026
- Structural Basis of Glycolytic Control in Trypanosoma cruzi: Insights from Enolase and PGI
Kenneth Austin, Vincent A Obakachi, … Graham Chakafana·bioRxiv·Jan 15, 2026
- Intrabody induced cell death by targeting the T. brucei cytoskeletal protein TbBILBO1
C. E. Broster-Reix, M. R. Ramanantsalama, … D. R. Robinson·bioRxiv·Jul 18, 2021
- The bloodstream form of Trypanosoma brucei displays non-canonical gluconeogenesis
J. Kovarova, M. Moos, … A. Zikova·bioRxiv·Apr 6, 2023